Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

Home/Insights/Research trends in obesity

Research trends in obesity

The field has moved from behavioural management toward pharmacological treatment of a chronic relapsing disease, and the research questions have moved with it.

Obesity and metabolic disease

The reframing

Obesity is now treated in the research literature as a chronic, relapsing, multifactorial disease with a strong physiological basis for weight regain, rather than as a behavioural failure. The practical consequence is that studies are designed around long-term maintenance rather than short-term loss.

Staging systems such as the Edmonton Obesity Staging System, which classify by the presence of complications rather than by BMI alone, reflect the recognition that BMI is a poor individual-level measure of health risk.

Incretin-based pharmacotherapy

The dominant line of research concerns GLP-1 receptor agonists and dual GLP-1/GIP agonists, which produce weight reduction of a magnitude previously achieved only surgically.

The questions that follow are the active ones: whether benefit extends to cardiovascular and other hard outcomes rather than weight alone; what happens on discontinuation, where regain is substantial; the composition of weight lost, particularly lean mass; tolerability and persistence; and cost and access, which determine whether efficacy translates into population benefit.

The other active areas

Metabolic and bariatric surgery, with long-term outcome data and comparison against pharmacotherapy. Weight regain physiology and adaptive thermogenesis. Obesity in specific contexts — adolescence, pregnancy, and alongside MASLD. Weight stigma as a measurable barrier to care. Heterogeneity of response, and whether responders can be identified in advance.

For authors in this area

Report weight outcomes as both absolute and percentage change, with the proportion achieving clinically meaningful thresholds. State the analysis approach for discontinuation, which is substantial in this literature and drives the headline figure. Report adverse events and persistence, not efficacy alone.

In short

What to take from this.

  • Report: discontinuation handling — it drives the headline result.
  • BMI is a population measure; complication-based staging is more informative individually.
  • Weight change alone is not a hard outcome.

Sources

  • Established reviews of incretin-based obesity pharmacotherapy
  • Edmonton Obesity Staging System literature

This page reflects established understanding as at mid-2026 and is not a current-awareness service. Clinical and regulatory positions change; verify anything decision-relevant against a current source.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.